301367SZSE

China International Capital Corporation's Verification Opinion on Beijing Ruimait Medical Technology Co., Ltd.'s 2025 Securities and Derivatives Investment

BMC Medical Co., Ltd.·April 22, 2026

✨ AI Summary

China International Capital Corporation (CICC) conducted a verification of Beijing Ruimait Medical Technology Co., Ltd.'s securities and derivatives investments for 2025. The company approved a foreign exchange hedging business with a limit of up to $250 million. CICC found no violations of relevant regulations, confirming that the decision-making process was legal and compliant.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Verification Opinion on Securities and Derivatives Investment

China International Capital Corporation (hereinafter referred to as "CICC" or "Sponsor") is the sponsor for the initial public offering and continuous supervision of Beijing Ruimait Medical Technology Co., Ltd. (hereinafter referred to as "Ruimait" or "Company"). In accordance with relevant laws, regulations, and business rules, CICC conducted a prudent verification of Ruimait's securities and derivatives investment situation for 2025 and issued the following verification opinion:

1. Approval of Securities and Derivatives Investment

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.